Dr. Walter Rayford

Dr. Walter Rayford
Member: Alliance for Academic Internal Medicine American Association for Cancer Research American Association of Clinical Urologists American Board of Urology American Medical Association American Society for Cell Biology American Urological Association National Medical Association Society of University Urologists Southeastern Section of the American Urological Association Southwest Oncology Group Dr. Rayford attended the University of Kansas where he received his doctorate (Ph.D.) in Biochemistry in 1987, and his Medical Degree in 1991. He completed general surgery training at St. Luke’s Hospital in Kansas City, MO, and urology training at the University of Kansas. Dr. Rayford completed a urologic oncology fellowship at the National Institutes of Health, National Cancer Institute in Bethesda, MD. He was certified by the American Board of Urology in February, 2002. Dr. Rayford has published extensively in the areas of prostate cancer, benign prostate hypertrophy and health disparities. He is an Associate Professor in the Department of Preventive Medicine at the University of Tennessee. He currently holds membership with the American Urology Association, American Association of Clinical Urologists, National Medical Association and R. Frank Jones Urological Society. He provides exceptional urological care to patients in East Memphis, Southaven and Holly Springs, Mississippi.
Medical School:

University of Kansas Medical School

Residency:

University of Kansas

Fellowship:

National Institutes of Health, National Cancer Institute in Bethesda, MD

Undergraduate:

Jackson State University

All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

Rx Only